Publications by authors named "Isabella Renzi"
Article Synopsis
- The study explores new mRNA vaccine strategies to enhance effectiveness against COVID-19, focusing on specific protein domains of the virus instead of the full-length spike protein.
- The candidate vaccine mRNA-1283, combining the N-terminal domain and receptor binding domain, shows better antigen expression, stronger antibody responses, and improved stability compared to existing vaccines.
- In animal tests, mRNA-1283 elicits equal or greater immune protection against various COVID-19 variants, supporting its advancement to clinical trials for further evaluation.
Article Synopsis
- * They engineered chimeric proteins by fusing parts of the SARS-CoV-2 Spike protein with HIV-1 or SIV sequences to enhance their effectiveness in producing VLPs, leading to increased cell-surface expression.
- * Mice immunized with the mRNA showed significantly higher antibody responses against the Spike protein and maintained effectiveness against various SARS-CoV-2 variants, suggesting the Gag/VLP mRNA platform's potential for creating vaccines against multiple infectious diseases.
Article Synopsis
- Researchers developed a new mRNA vaccine, mRNA-1283, targeting specific spike protein domains of the virus responsible for COVID-19.
- This vaccine demonstrated enhanced antigen expression, antibody responses, and stability when stored in refrigerated conditions compared to the existing mRNA-1273 vaccine.
- In preclinical tests, mRNA-1283 provided similar or better immune protection against various COVID-19 variants in mice, indicating its potential for human clinical trials.
The large number of spike substitutions in Omicron lineage variants (BA.1, BA.1.
View Article and Find Full Text PDFSARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron.
View Article and Find Full Text PDFThe Omicron variant of SARS-CoV-2 has been shown to evade neutralizing antibodies elicited by vaccination or infection. Despite the global spread of the Omicron variant, even among highly vaccinated populations, death rates have not increased concomitantly. These data suggest that immune mechanisms beyond antibody-mediated virus neutralization may protect against severe disease.
View Article and Find Full Text PDFA vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity. This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation.
View Article and Find Full Text PDFA SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273).
View Article and Find Full Text PDF